|
WO2000045849A2
(en)
*
|
1999-02-05 |
2000-08-10 |
Genzyme Corporation |
Use of cationic lipids to generate anti-tumor immunity
|
|
IL147127A0
(en)
*
|
1999-06-22 |
2002-08-14 |
Res Dev Foundation |
Method to enhance wound healing and enhanced wound coverage material
|
|
ES2256043T3
(es)
*
|
1999-10-01 |
2006-07-16 |
Lipoxen Technologies Limited |
Vacunas de uso oral que contienen liposomas y adn atrapado.
|
|
US7381421B2
(en)
|
1999-12-13 |
2008-06-03 |
Lipoxen Technologies Limited |
Liposomes
|
|
US6372250B1
(en)
*
|
2000-04-25 |
2002-04-16 |
The Regents Of The University Of California |
Non-invasive gene targeting to the brain
|
|
DE10109897A1
(de)
*
|
2001-02-21 |
2002-11-07 |
Novosom Ag |
Fakultativ kationische Liposomen und Verwendung dieser
|
|
DE60310562T2
(de)
|
2002-07-05 |
2007-10-11 |
Lipoxen Technologies Ltd. |
Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
|
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
JP4546115B2
(ja)
*
|
2004-03-05 |
2010-09-15 |
三菱化学メディエンス株式会社 |
細胞中ａｔｐの定量法
|
|
DE102004057303A1
(de)
*
|
2004-11-26 |
2006-06-01 |
Merck Patent Gmbh |
Stabile Kristallmodifikationen von DOTAP Chlorid
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
CN100400667C
(zh)
*
|
2006-06-27 |
2008-07-09 |
浙江大学 |
脂质体包裹弓形虫pGRA4真核表达质粒的方法及用途
|
|
NZ578541A
(en)
|
2006-12-22 |
2012-04-27 |
Soluciones Biotecnologicas Innovacion Ltda |
Dna vaccines for fish
|
|
RU2367443C1
(ru)
*
|
2008-02-28 |
2009-09-20 |
Общество с ограниченной ответственностью "Битеп" |
Средство на основе природных фосфолипидов
|
|
EP2184054A1
(en)
|
2008-11-08 |
2010-05-12 |
Lipoxen Technologies Limited |
Small Interfering RNA Delivery
|
|
WO2011005772A1
(en)
|
2009-07-06 |
2011-01-13 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
|
EP2451950B9
(en)
*
|
2009-07-06 |
2016-11-23 |
Variation Biotechnologies Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
|
US12419839B2
(en)
|
2009-10-09 |
2025-09-23 |
Signablok, Inc. |
Methods and compositions for targeted delivery of protein fragments
|
|
US10894098B2
(en)
|
2012-04-09 |
2021-01-19 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
|
WO2011044545A2
(en)
|
2009-10-09 |
2011-04-14 |
Sigalov Alexander B |
Methods and compositions for targeted imaging
|
|
EP3318248B1
(en)
|
2009-12-01 |
2019-04-10 |
Translate Bio, Inc. |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
|
WO2011136368A1
(ja)
*
|
2010-04-28 |
2011-11-03 |
協和発酵キリン株式会社 |
カチオン性脂質
|
|
CA2840079C
(en)
|
2010-07-06 |
2018-07-03 |
Variation Biotechnologies Inc. |
Compositions and methods for treating influenza
|
|
CN103052400B
(zh)
|
2010-07-06 |
2016-11-16 |
诺华股份有限公司 |
自我复制rna分子的病毒样递送颗粒
|
|
US9801897B2
(en)
|
2010-07-06 |
2017-10-31 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to trigger multiple immune pathways
|
|
ES2557382T3
(es)
|
2010-07-06 |
2016-01-25 |
Glaxosmithkline Biologicals Sa |
Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
|
|
CA2804492A1
(en)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Immunisation of large mammals with low doses of rna
|
|
CN108042799A
(zh)
|
2010-07-06 |
2018-05-18 |
诺华股份有限公司 |
阳离子水包油乳液
|
|
EP4226941B1
(en)
|
2010-08-31 |
2024-10-23 |
GlaxoSmithKline Biologicals SA |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
KR102162111B1
(ko)
|
2010-10-11 |
2020-10-07 |
노파르티스 아게 |
항원 전달 플랫폼
|
|
CN103501811B
(zh)
|
2011-01-13 |
2016-03-30 |
变异生物技术公司 |
用于治疗病毒感染的组合物和方法
|
|
RU2491062C2
(ru)
*
|
2011-03-16 |
2013-08-27 |
Общество С Ограниченной Ответственностью "Биотехнологии Пущино" |
Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий
|
|
RU2670745C9
(ru)
|
2011-05-24 |
2018-12-13 |
Бионтех Рна Фармасьютикалс Гмбх |
Индивидуализированные противоопухолевые вакцины
|
|
BR112013031553A2
(pt)
|
2011-06-08 |
2020-11-10 |
Shire Human Genetic Therapies, Inc. |
composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
|
|
EP3332802A1
(en)
|
2011-07-06 |
2018-06-13 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
CN103796639B
(zh)
|
2011-07-06 |
2017-05-31 |
诺华股份有限公司 |
阳离子水包油乳液
|
|
JP6059220B2
(ja)
|
2011-07-06 |
2017-01-18 |
ノバルティス アーゲー |
核酸を含む水中油型エマルジョン
|
|
CA2894442C
(en)
|
2012-01-12 |
2020-01-21 |
Variation Biotechnologies Inc. |
Compositions and methods for treating viral infections
|
|
EP4008354A1
(en)
|
2012-01-27 |
2022-06-08 |
Variation Biotechnologies Inc. |
Methods and compositions for therapeutic agents
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
EP3536787A1
(en)
|
2012-06-08 |
2019-09-11 |
Translate Bio, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
AU2013271392B2
(en)
|
2012-06-08 |
2018-02-15 |
Ethris Gmbh |
Pulmonary delivery of mRNA to non-lung target cells
|
|
EP2925348B1
(en)
|
2012-11-28 |
2019-03-06 |
BioNTech RNA Pharmaceuticals GmbH |
Individualized vaccines for cancer
|
|
WO2014152966A1
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Methods for purification of messenger rna
|
|
KR102248744B1
(ko)
|
2013-03-14 |
2021-05-06 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Cftr mrna 조성물 및 관련 방법 및 사용
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
MX381303B
(es)
|
2013-10-22 |
2025-03-12 |
Shire Human Genetic Therapies |
Composición que comprende un ácido ribonucleico mensajero que codifica argininosuccinato sintetasa para usarse en el tratamiento de la deficiencia de argininosuccinato sintetasa.
|
|
JP6506749B2
(ja)
|
2013-10-22 |
2019-04-24 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
フェニルケトン尿症のためのｍＲＮＡ療法
|
|
AU2014369969A1
(en)
*
|
2013-12-27 |
2016-07-28 |
Teloregen, Inc. |
Compositions and methods for providing active telomerase to cells in vivo
|
|
JP6546195B2
(ja)
*
|
2014-01-17 |
2019-07-17 |
フンダシオ・インスティトゥート・ディンベスティガシオ・エン・シエンシス・デ・ラ・サルー・ヘルマンス・トリアス・イ・プホル |
リポソームに基づく免疫療法
|
|
KR20250005450A
(ko)
|
2014-04-25 |
2025-01-09 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna 의 정제 방법
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
EA201991747A1
(ru)
|
2017-02-27 |
2020-06-04 |
Транслейт Био, Инк. |
НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
|
|
EP3624824B1
(en)
|
2017-05-16 |
2024-07-10 |
Translate Bio, Inc. |
Codon-optimized mrna encoding cftr for use in treating cystic fibrosis
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
WO2020041793A1
(en)
|
2018-08-24 |
2020-02-27 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
WO2020106946A1
(en)
|
2018-11-21 |
2020-05-28 |
Translate Bio, Inc. |
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
|
|
EP3892260A1
(en)
*
|
2020-04-10 |
2021-10-13 |
Bayer Animal Health GmbH |
Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
|
|
CA3210451A1
(en)
|
2021-03-22 |
2022-09-29 |
Illumina Cambridge Limited |
Methods for improving nucleic acid cluster clonality
|